跳至主要内容
临床试验/EUCTR2019-003828-21-NL
EUCTR2019-003828-21-NL进行中(未招募)1 期

Identification of sentinel lymph nodes in breast cancer patients through non-invasively and percutaneously fluorescent imaging using indocyanine green - INFLUENCE

St Antonius Hospital0 个研究点目标入组 100 人开始时间: 2020年1月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - Clinically node-negative, invasive early T1 or T2 breast cancer confirmed by biopsy.
  • - Preoperative axillary ultrasound to confirm clinical node-negative status.
  • - Indication for lumpectomy and SLN procedure.
  • - Written informed consent according to ICH/GCP and national regulations.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 100

排除标准

  • -Patients < 18 years old.
  • -Mastectomy.
  • -Known allergy for indocyanine green (ICG) or radioisotope technetium (99mTc) or intravenous contrast, iodine, shellfish.
  • -Other concurrent solid tumor.
  • -Hyperthyroidism or thyroid cancer.
  • -Palliative surgery for locally advanced breast cancer (cT4).
  • -Pregnancy or breast feeding.
  • -Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol.

研究者

相似试验